Payment overview · 2025
General Payments
$167.42
9 reported records · 6 companies
Healthcare provider profile · identity verified
Terry Pitts, DO
Allopathic & Osteopathic Physicians|Family Medicine · LAUREL, MS · NPI 1699714311
Verified facts
What the public records show
CMS Open Payments records show Terry Pitts, DO received $167.42 in general payments during 2025 across 9 reported records.
Insulet Corporation accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insulet Corporation | Unresolved — no canonical attribution shown | $39.52 | 23.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.37 | 21.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.13 | 20.4% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.47 | 14.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.39 | 11.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.54 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $167.42 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $39.52 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.37 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 604 | 144 |
| Gabapentin | Gabapentin | 455 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 106 |
| Metformin Hcl | Metformin Hcl | 395 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 381 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 353 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 304 | 95 |
| Omeprazole | Omeprazole | 298 | 62 |
| Trazodone Hcl | Trazodone Hcl | 275 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 248 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 46 |
| Meloxicam | Meloxicam | 240 | 63 |
| Lisinopril | Lisinopril | 237 | 57 |
| Potassium Chloride | Potassium Chloride | 219 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 55 |
| Carvedilol | Carvedilol | 206 | 44 |
| Losartan Potassium | Losartan Potassium | 193 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 48 |
| Glimepiride | Glimepiride | 160 | 39 |
| Alendronate Sodium | Alendronate Sodium | 155 | 41 |
| Furosemide | Furosemide | 154 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 37 |
| Pregabalin | Pregabalin | 135 | 31 |
| Allopurinol | Allopurinol | 132 | 34 |
| Simvastatin | Simvastatin | 126 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 33 |
| Linzess | Linaclotide | 122 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 121 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 31 |
| Tramadol Hcl | Tramadol Hcl | 113 | 27 |
| Montelukast Sodium | Montelukast Sodium | 105 | 32 |
| Farxiga | Dapagliflozin Propanediol | 104 | 26 |
| Sertraline Hcl | Sertraline Hcl | 104 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 26 |
| Buspirone Hcl | Buspirone Hcl | 98 | 23 |
| Alprazolam | Alprazolam | 96 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 16 |
| Ezetimibe | Ezetimibe | 90 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 24 |
| Donepezil Hcl | Donepezil Hcl | 84 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 19 |
| Baclofen | Baclofen | 77 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 15 |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | suppressed |
| Estradiol | Estradiol | 60 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Jardiance | Empagliflozin | 58 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 15 |
| Spironolactone | Spironolactone | 55 | 16 |
| Doxepin Hcl | Doxepin Hcl | 50 | suppressed |
| Famotidine | Famotidine | 49 | 13 |
| Topiramate | Topiramate | 49 | 12 |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Glipizide | Glipizide | 46 | 16 |
| Memantine Hcl | Memantine Hcl | 46 | 16 |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Eliquis | Apixaban | 45 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 13 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 17 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Fluconazole | Fluconazole | 31 | 22 |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | 11 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Glyburide | Glyburide | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $167.42 · 9 records | Insulet Corporation | FARXIGA, JARDIANCE, Kerendia, Omnipod, Ozempic, QUTENZA, Rybelsus | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error